Clinical Trial Update: FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (FLASH-Breast) is evaluating fezolinetant to reduce vasomotor symptoms in women with breast cancer on endocrine therapy; the study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fezolinetant (fezolinetant)

Snippet

Sponsor: Yale University | Conditions: Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Phase 2 | Status: RECRUITING